What is Nanjing Hicin Pharmaceutical Co Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Sep. 2024, Nanjing Hicin Pharmaceutical Co has a Sloan Ratio of 7.75%, indicating the company is in the safe zone and there is no funny business with accruals.
Nanjing Hicin Pharmaceutical Co Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Nanjing Hicin Pharmaceutical Co Sloan Ratio % Chart
Competitive Comparison of Nanjing Hicin Pharmaceutical Co's Sloan Ratio %
For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing Hicin Pharmaceutical Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Hicin Pharmaceutical Co's Sloan Ratio % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanjing Hicin Pharmaceutical Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Nanjing Hicin Pharmaceutical Co's Sloan Ratio % falls into.
Nanjing Hicin Pharmaceutical Co Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Nanjing Hicin Pharmaceutical Co's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was 13.893 (Dec. 2023 ) + 13.358 (Mar. 2024 ) + 11.379 (Jun. 2024 ) + 3.38 (Sep. 2024 ) = ¥42.0 Mil.
Nanjing Hicin Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was 4.458 (Dec. 2023 ) + 4.681 (Mar. 2024 ) + 31.951 (Jun. 2024 ) + 7.314 (Sep. 2024 ) = ¥48.4 Mil.
Nanjing Hicin Pharmaceutical Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was -57.108 (Dec. 2023 ) + -29.32 (Mar. 2024 ) + -14.254 (Jun. 2024 ) + -15.984 (Sep. 2024 ) = ¥-116.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Hicin Pharmaceutical Co (SZSE:300584) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Sep. 2024, Nanjing Hicin Pharmaceutical Co has a Sloan Ratio of 7.75%, indicating the company is in the safe zone and there is no funny business with accruals.
Nanjing Hicin Pharmaceutical Co Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Nanjing Hicin Pharmaceutical Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Nanjing Hicin Pharmaceutical Co Business Description
Nanjing Hicin Pharmaceutical Co Ltd is a China-based company engaged in producing pharmaceutical preparations. In addition, it is also involved in manufacturing synthetic chemicals, conducting new drug research and development as well as technical transferring. The company produces series of the medicines such as antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for the cardio-cerebral system and immuno-modulate agents. The active pharmaceutical ingredients, omeprazole sodium for injection, cefepime hydrochloride for Injection and lansoprazole tablets are exported by the firm into South-Asian countries, South-American countries and European countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SZSE:300584 has been successfully added to your 